Guggenheim downgraded shares of Centessa Pharmaceuticals (NASDAQ:CNTA – Free Report) from a buy rating to a hold rating in a research note published on Thursday, Marketbeat.com reports.
CNTA has been the subject of several other research reports. Oppenheimer raised their target price on Centessa Pharmaceuticals from $40.00 to $62.00 and gave the stock an “outperform” rating in a research note on Wednesday, December 10th. Lifesci Capital cut Centessa Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Wednesday. Leerink Partners downgraded shares of Centessa Pharmaceuticals from an “outperform” rating to a “hold” rating and increased their price target for the stock from $36.00 to $40.00 in a report on Wednesday. Stephens cut shares of Centessa Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, March 31st. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Centessa Pharmaceuticals in a report on Wednesday, January 21st. Six analysts have rated the stock with a Buy rating, seven have assigned a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, Centessa Pharmaceuticals has a consensus rating of “Hold” and a consensus target price of $40.00.
Get Our Latest Stock Report on Centessa Pharmaceuticals
Centessa Pharmaceuticals Stock Performance
Centessa Pharmaceuticals (NASDAQ:CNTA – Get Free Report) last announced its quarterly earnings results on Tuesday, March 31st. The company reported ($0.48) earnings per share for the quarter, missing the consensus estimate of ($0.38) by ($0.10). As a group, analysts expect that Centessa Pharmaceuticals will post -1.6 EPS for the current year.
Insider Buying and Selling at Centessa Pharmaceuticals
In related news, insider Karen M. Anderson sold 41,076 shares of the firm’s stock in a transaction dated Thursday, March 26th. The stock was sold at an average price of $30.12, for a total transaction of $1,237,209.12. Following the transaction, the insider directly owned 62,085 shares of the company’s stock, valued at approximately $1,870,000.20. This trade represents a 39.82% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, insider Iqbal J. Hussain sold 38,951 shares of the business’s stock in a transaction that occurred on Monday, February 2nd. The stock was sold at an average price of $25.15, for a total value of $979,617.65. Following the completion of the sale, the insider owned 57,645 shares of the company’s stock, valued at $1,449,771.75. The trade was a 40.32% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold 349,073 shares of company stock worth $9,429,412 over the last 90 days. Corporate insiders own 7.09% of the company’s stock.
Institutional Inflows and Outflows
A number of institutional investors and hedge funds have recently bought and sold shares of CNTA. Virtus Investment Advisers LLC raised its stake in shares of Centessa Pharmaceuticals by 6.2% during the fourth quarter. Virtus Investment Advisers LLC now owns 10,034 shares of the company’s stock worth $251,000 after acquiring an additional 583 shares in the last quarter. China Universal Asset Management Co. Ltd. grew its holdings in shares of Centessa Pharmaceuticals by 4.8% during the 2nd quarter. China Universal Asset Management Co. Ltd. now owns 19,181 shares of the company’s stock valued at $252,000 after purchasing an additional 870 shares during the last quarter. Coastal Bridge Advisors LLC raised its position in Centessa Pharmaceuticals by 7.1% in the 4th quarter. Coastal Bridge Advisors LLC now owns 14,033 shares of the company’s stock worth $351,000 after purchasing an additional 931 shares during the period. Mirae Asset Global Investments Co. Ltd. raised its position in Centessa Pharmaceuticals by 26.4% in the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 4,688 shares of the company’s stock worth $117,000 after purchasing an additional 979 shares during the period. Finally, TD Waterhouse Canada Inc. bought a new stake in Centessa Pharmaceuticals in the fourth quarter worth $25,000. 82.01% of the stock is currently owned by institutional investors.
Key Headlines Impacting Centessa Pharmaceuticals
Here are the key news stories impacting Centessa Pharmaceuticals this week:
- Positive Sentiment: Unusually large purchase of call options — shows bullish speculative interest and potential short-term demand from options traders, which can support the equity even as analysts trim ratings. Investors Purchase High Volume of Centessa Pharmaceuticals Call Options
- Neutral Sentiment: High overall options activity flagged — elevated options volume was reported, but the report does not fully clarify position directions (mix of puts/calls), so the net impact is uncertain. Centessa Pharmaceuticals Target of Unusually High Options Trading
- Negative Sentiment: Guggenheim downgraded CNTA from “buy” to “hold” — a notable sell-side cut from a sizable shop that reduces buy-side conviction and can pressure the stock. Guggenheim downgrades Centessa Pharmaceuticals plc – Depositary Receipt (CNTA)
- Negative Sentiment: Leerink Partners lowered its rating to “hold” — another research downgrade that contributes to negative analyst sentiment. Centessa Pharmaceuticals (NASDAQ:CNTA) Rating Lowered to “Hold” at Leerink Partners
- Negative Sentiment: Stephens cut CNTA to “hold” — adds to a cluster of downgrades from independent research shops. Centessa Pharmaceuticals (NASDAQ:CNTA) Cut to Hold at Stephens
- Negative Sentiment: Multiple other firms (Wolfe Research, Needham, B. Riley and Lifesci Capital) trimmed ratings or moved from “strong-buy” to “hold” — broad-based analyst downgrades increase selling pressure and reduce near-term upside expectations. Wolfe Research Downgrades Centessa Pharmaceuticals to Hold Needham & Company LLC Lowers Rating B. Riley / Lifesci coverage notes
About Centessa Pharmaceuticals
Centessa Pharmaceuticals plc is a global clinical‐stage biopharmaceutical company focused on the discovery and development of innovative therapies across multiple disease areas. The company operates a modular R&D network, bringing together a portfolio of independent, specialist research entities under a single corporate umbrella. This structure is designed to accelerate decision‐making and resource allocation while leveraging deep scientific expertise in each therapeutic domain.
Centessa’s pipeline spans oncology, immunology, neuroscience, cardiovascular and metabolic diseases, as well as rare genetic disorders.
See Also
Receive News & Ratings for Centessa Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Centessa Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
